FTC Finalizes Amendments to HSR Act to Expand Reporting Requirements for Pharmaceutical Patent Licenses

The Federal Trade Commission (“FTC”) has finalized proposed amendments to the premerger notification rules that will require firms operating in the pharmaceutical industry to comply with the Hart-Scott-Rodino Antitrust Improvements Act (“Act”) when transferring or licensing “all commercially significant rights” to a patent.